Corient Private Wealth
ERNA icon

Corient Private Wealth’s Eterna Therapeutics ERNA Stock Holding History

Corient Private Wealth’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,524
Closed -$87.2K – 3111
2026
Q1 		$87.2K Sell
17,524
-17,523
-50% -$280K ﹤0.01% 2711
2025
Q4 		$1.05M Buy
35,047
+17,523
+100% +$597K ﹤0.01% 1855
2025
Q3 		$480K Buy
17,524
+16,823
+2,400% +$667K ﹤0.01% 1813
2025
Q2 		$32.2K Hold
701
– – ﹤0.01% 2404
2025
Q1 		$46.8K Hold
701
– – ﹤0.01% 2229
2024
Q4 		$77.3K Hold
701
– – ﹤0.01% 2246
2024
Q3 		$276K Buy
701
+567
+423% +$363K ﹤0.01% 2049
2024
Q2 		$91.2K Hold
134
– – ﹤0.01% 2219
2024
Q1 		$120K Hold
134
– – ﹤0.01% 2164
2023
Q4 		$90.2K Sell
134
-3
-2% -$1.72K ﹤0.01% 2165
2023
Q3 		$116K Sell
137
-24
-15% -$22.1K ﹤0.01% 2004
2023
Q2 		$134K Sell
161
-2
-1% -$2.02K ﹤0.01% 1943
2023
Q1 		$214K Hold
163
– – ﹤0.01% 1768
2022
Q4 		$197K Buy
+163
New +$230K ﹤0.01% 1497

Other funds holding ERNA

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Corient Private Wealth's ERNA Position: Q2 2026 in Review

Corient Private Wealth sold out of Eterna Therapeutics (ERNA) in Q2 2026, closing a stake of 17,524 shares — an estimated $87.2K sold.

Corient Private Wealth first reported a position in ERNA in Q4 2022 and held it in 14 quarters. The position peaked at $1.05M in Q4 2025. 8 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Corient Private Wealth reported no remaining Eterna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Corient Private Wealth sold 17,524 Eterna Therapeutics shares in Q2 2026, an estimated $87.2K.
  • Corient Private Wealth first reported a position in Eterna Therapeutics in Q4 2022 and held it in 14 quarters.
  • Corient Private Wealth's Eterna Therapeutics position peaked at $1.05M in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.